According to Outsourcing Pharma, clinical trials initiated annually in South Korea increased by 150 per cent between 2006 and 2009 making this the next key destination for the clinical trials sector.
Despite language barriers and regulations being some of the top barriers of entry, South Korea has received significant government support and investment, especially in the biotechnology sector, making it an attractive destination. In addition to investors and foreign investment from multinational companies that have been funding the clinical trials sector and with similar cost benefits, rapid recruitment and better innovation have put South Korea ahead of it's Asian neighbours as the next stop for the clinical trials sector.
We interviewed over 350 industry professionals, to find out their views on South Korea's clinical trials industry. In this survey report, find out what the most therapeutical areas for organizations are in the coming year, what challenges organizations face in the area of clinical trials, and what are important clinical trial related strategic areas for the next year.
Find out how to accelerate clinical development, access emerging markets, and enhance clinical operations at Pharma Trials Korea, taking place July 2013.
For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D